Persistence of HIV-1 structural proteins and glycoproteins in lymph nodes of patients under highly active antiretroviral therapy. - Wikidata - wikimedia - TriplyDB

Persistence of HIV-1 structural proteins and glycoproteins in lymph nodes of patients under highly active antiretroviral therapy.

Persistence of HIV-1 structural proteins and glycoproteins in lymph nodes of patients under highly active antiretroviral therapy.

http://www.wikidata.org/entity/Q34078508

about

Akt inhibitors as an HIV-1 infected macrophage-specific anti-viral therapy A lymphomagenic role for HIV beyond immune suppression?The HIV matrix protein p17 subverts nuclear receptors expression and induces a STAT1-dependent proinflammatory phenotype in monocytes Functional stability of unliganded envelope glycoprotein spikes among isolates of human immunodeficiency virus type 1 (HIV-1)[The Competence Network for HIV/AIDS. Data, Samples, Facts].HIV-1 gp120 mannoses induce immunosuppressive responses from dendritic cells.Simian immunodeficiency virus and human immunodeficiency virus type 1 matrix proteins specify different capabilities to modulate B cell growth.Plasmacytoid dendritic cells accumulate and secrete interferon alpha in lymph nodes of HIV-1 patients.Opposite effects of HIV-1 p17 variants on PTEN activation and cell growth in B cells.South African Breast Cancer and HIV Outcomes Study: Methods and Baseline Assessment.R5-SHIV induces multiple defects in T cell function during early infection of rhesus macaques including accumulation of T reg cells in lymph nodes X4 Human immunodeficiency virus type 1 gp120 promotes human hepatic stellate cell activation and collagen I expression through interactions with CXCR4 HIV-1 infection is associated with changes in nuclear receptor transcriptome, pro-inflammatory and lipid profile of monocytes.Naive T-cell depletion related to infection by X4 human immunodeficiency virus type 1 in poor immunological responders to highly active antiretroviral therapy.HIV-1 immune activation induces Siglec-1 expression and enhances viral trans-infection in blood and tissue myeloid cells.HIV-associated lymphoma in the era of combination antiretroviral therapy: shifting the immunological landscape HIV-1 p17 matrix protein interacts with heparan sulfate side chain of CD44v3, syndecan-2, and syndecan-4 proteoglycans expressed on human activated CD4+ T cells affecting tumor necrosis factor alpha and interleukin 2 production.Contribution of HIV infection to mortality among cancer patients in Uganda.Blocking type I interferon production: a new therapeutic option to reduce the HIV-1-induced immune activation How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development?HIV-1 Structural Proteins Serve as PAMPs for TLR2 Heterodimers Significantly Increasing Infection and Innate Immune Activation.Follicular Regulatory CD8 T Cells Impair the Germinal Center Response in SIV and Ex Vivo HIV Infection.Expansion of HIV-specific T follicular helper cells in chronic HIV infection.HIV-1 matrix protein p17 promotes angiogenesis via chemokine receptors CXCR1 and CXCR2.Angiogenic, lymphangiogenic and adipogenic effects of HIV-1 matrix protein p17.Role of HIV-1 matrix protein p17 variants in lymphoma pathogenesis.The α7-nicotinic receptor is upregulated in immune cells from HIV-seropositive women: consequences to the cholinergic anti-inflammatory response HIV-1 matrix protein p17 induces human plasmacytoid dendritic cells to acquire a migratory immature cell phenotype.Molecular interaction studies of HIV-1 matrix protein p17 and heparin: identification of the heparin-binding motif of p17 as a target for the development of multitarget antagonists Immune reconstitution disease associated with parasitic infections following antiretroviral treatment.Tissue reservoirs of HIV Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs Inadequate T follicular cell help impairs B cell immunity during HIV infection.B cell lymphoma in HIV transgenic mice.HIV-1 evades virus-specific IgG2 and IgA responses by targeting systemic and intestinal B cells via long-range intercellular conduits.Expression of HIV-1 matrix protein p17 and association with B-cell lymphoma in HIV-1 transgenic mice.Spatial modeling of HIV cryptic viremia and 2-LTR formation during raltegravir intensification.Role of inflammation in HIV-1 disease progression and prognosis.Effect of Chromium(VI) Toxicity on Enzymes of Nitrogen Metabolism in Clusterbean (Cyamopsis tetragonoloba L.).Increased, durable B-cell and ADCC Responses Associated with T-helper Responses to HIV-1 Envelope in Macaques Vaccinated with gp140 Occluded at the CD4 Receptor Binding Site.

P2860

Q24655510-BB14BA7E-CD1C-4FB4-8BCA-02ACEB175182 Q26771672-E4C9947C-92D1-4DE5-B6DE-926317038CE6 Q28730200-CC1B473D-B9D4-4505-9925-3219F2F13D92 Q28743199-5D4A10A2-C2A6-42D2-B2B3-8BB21C8BBA38 Q31056307-CF3F6BE4-27BC-48C2-BDC7-08B417F1EC22 Q33305012-2D908EC0-3711-4730-AA20-88DA1D12E665 Q33602706-84D6093B-ABAE-405B-84BD-5E5D1529A10E Q33608661-E7E232CB-7E84-4939-9263-E84C4CDCBB67 Q33851786-47DB41E6-4C0F-4136-BAEC-A6765E148D4F Q33859760-9C79C949-A52A-4CD8-8A17-1EF7223AA7FD Q33869259-B36C1A61-88D6-4D94-B968-CD20E614C644 Q34221539-3879F56D-4945-45D8-8A36-4B08895B4FC1 Q34459345-02B6C262-3A19-4400-A3B2-C8389AABF9A6 Q34569382-F8A14A57-51CA-4D32-81A0-12E82F1686A3 Q34669697-9F950418-C5AE-4F72-97ED-ECAF91BA05C7 Q34671009-30BC86FB-37B6-4A56-91C4-71488FB0105C Q35010983-45FCE579-AFFC-417D-8349-489410C5C3B1 Q35056551-4820F30C-A83E-49C6-A506-35D88E7A6A4B Q35606616-1451C3D7-052B-4C7E-8306-AE608DD0A4EC Q35653703-4763956F-5A0E-4887-85F8-135ED9DCE7C0 Q35970108-622657F7-8102-4415-A438-F726382C1D13 Q36157766-E4DCA2A7-E8FC-4A5B-9F2C-445504E3097D Q36190755-9CDFD2F2-1A5C-4B90-A051-D3A2E69B03CA Q36221840-E12026CC-A744-4278-8A5C-8287592755C3 Q36226553-5A4E9C0D-1613-4A43-9655-16B4362E78B6 Q36306025-2C7A3F3F-2C9A-4611-82D5-4F9B68B9A65B Q36388273-BAC4510C-A943-451A-9CC7-7E9C28BF8700 Q36499042-466D87D9-F55C-4E6F-96B9-ECD73C87C974 Q36526260-6866B694-99F0-4C9D-96E6-7172D095D698 Q36624200-379BE53E-EB6C-4E17-B179-67E8FC295EF5 Q37055454-F72C3A1A-5667-493D-90D5-2347B5F8E0B3 Q37273652-97A997BC-01C9-4FD8-B5E2-A39F58630DD6 Q37349638-FE05A555-76BE-4B90-AA19-7B938BDEF2A2 Q37356765-2805E9EE-174A-4BF5-ACA9-A471D47BCCDE Q37444317-E599E885-8D86-4912-92DC-B337B7C830EF Q37469500-E72B252C-9762-44CC-84DA-86D7EF1D5562 Q37621893-DEC5CF0D-F81F-4DFF-98F5-C7A45A2E3ECE Q38183454-8763A8DE-C535-4200-AD8C-5DAB0277FDB6 Q38626710-5974AD0C-231D-4B09-A9D9-9E6F6A97E969 Q38658529-B5940D66-2EDA-483A-8977-73F4C9BF49F6

P2860

Persistence of HIV-1 structural proteins and glycoproteins in lymph nodes of patients under highly active antiretroviral therapy.

http://www.wikidata.org/entity/Q34078508

description

2005 nî lūn-bûn

@nan

2005 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

name

Persistence of HIV-1 structura ...... active antiretroviral therapy.

@ast

Persistence of HIV-1 structura ...... active antiretroviral therapy.

@en

Persistence of HIV-1 structura ...... active antiretroviral therapy.

@nl

type

label

Persistence of HIV-1 structura ...... active antiretroviral therapy.

@ast

Persistence of HIV-1 structura ...... active antiretroviral therapy.

@en

Persistence of HIV-1 structura ...... active antiretroviral therapy.

@nl

prefLabel

Persistence of HIV-1 structura ...... active antiretroviral therapy.

@ast

Persistence of HIV-1 structura ...... active antiretroviral therapy.

@en

Persistence of HIV-1 structura ...... active antiretroviral therapy.

@nl

P1433

Q34078508-326A361C-A196-4ABD-A533-D6BBFC1327AE

P1476

Q34078508-1397E9A6-15D5-40BF-BDA7-DD277E125476

P2093

Q34078508-00CE4496-0717-4C9B-8A99-E8912A1AE7AC

Q34078508-0694818C-081A-4996-BAF2-BDA1DF7E6B15

Q34078508-4908CAEA-3D23-481A-9D79-A59E84576E44

Q34078508-4A52B552-A5DA-4D3E-BC6C-1F03D1D7097E

Q34078508-5925CAB0-1E09-447C-86C6-44B725A60829

Q34078508-D339B6F8-B99A-4790-AA2A-5E8C3BFCD29A

Q34078508-FD6614B8-EDFF-4385-9251-E80B013272B7

P2860

Q34078508-0325EFF4-6EEA-4318-9C59-1A7012C0ACD7

Q34078508-05B3BC03-820A-45F7-B2AB-2CC66B1CCA9F

Q34078508-0765CE6A-DF9C-402E-8FCF-3779A92A917F

Q34078508-08E1C26F-0B9C-4191-802A-220133884A02

Q34078508-18AF9277-BD20-4C00-AB22-49C125D448D0

Q34078508-1E26939C-ECF2-49EB-BD3C-B78782DDE44A

Q34078508-1FA412F2-505A-4A14-A522-BEAFF2C1CE87

Q34078508-28E38B2B-D7A4-4BF7-A90B-4A7196B4926F

Q34078508-29F68E32-D0E2-4772-8C31-7BE4CBFB17E7

Q34078508-2C4F5982-A6DD-4CAC-A816-6A52607B441D

P304

Q34078508-C3C02778-1A39-4CBF-93EA-4297B72DD2E1

P31

Q34078508-42AA1C88-0169-432A-94D9-EB5FCE5036FC

P356

Q34078508-206C64CF-9DB2-4317-A374-AEF53F9729F3

P407

Q34078508-4D9F9957-03AE-4412-B3F1-5261A1534592

P433

Q34078508-C6F007D1-FBDA-4129-9CE6-5E7AB8A9E02B

P478

Q34078508-CC954A2C-7866-45CD-ADB5-574DC40DDD8F

P50

Q34078508-0BD125F5-DAD3-4EC1-8204-F59CDE2C045D

Q34078508-ADA5493A-0F6E-4C78-8F05-9C1ECCC46A43

P577

Q34078508-0DDB9A95-E74A-40DD-9F67-3DA04FB5162F

P5875

Q34078508-19C8962E-2CC0-40E6-B05D-E25AB89E61B1

P698

Q34078508-962A2F58-2F57-486A-9668-A308F091187A

P921

Q34078508-5A7F55C3-84E6-48AA-9530-ACC132D92DC2

Q34078508-865CE05B-040C-4BEE-A559-B39AF75604B0

Q34078508-AB72B07A-0889-4940-9DE0-B9B8E648F4E9

Q34078508-B5C6B486-383A-4821-B602-17E38DC4135B

P932

Q34078508-D208ACC6-78CE-4B1A-B9BB-5B8295AD0C61

P356

PNAS.0506857102

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Persistence of HIV-1 structura ...... active antiretroviral therapy.

@en

P2093

Colleen Pelser

http://www.w3.org/2001/XMLSchema#string

George Lewis

http://www.w3.org/2001/XMLSchema#string

Hans-Jurgen Stellbrink

http://www.w3.org/2001/XMLSchema#string

Klara Tenner-Racz

http://www.w3.org/2001/XMLSchema#string

Mikulas Popovic

http://www.w3.org/2001/XMLSchema#string

Paul Racz

http://www.w3.org/2001/XMLSchema#string

Vaniambadi S Kalyanaraman

http://www.w3.org/2001/XMLSchema#string

P2860

Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection

Viral carcinogenesis: revelation of molecular mechanisms and etiology of human disease.

Antibody-mediated neutralization of primary human immunodeficiency virus type 1 isolates: investigation of the mechanism of inhibition.

An HIV-1 transgenic rat that develops HIV-related pathology and immunologic dysfunction.

HIV-1 induces phenotypic and functional perturbations of B cells in chronically infected individuals.

The molecular basis of acquired immunodeficiency syndrome-related lymphomagenesis.

HIV-1 matrix protein p17 increases the production of proinflammatory cytokines and counteracts IL-4 activity by binding to a cellular receptor.

Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques

On differences between immunity and immunological memory.

Reassessing the function of immune-complex retention by follicular dendritic cells.

P304

14807-14812

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.0506857102

http://www.w3.org/2001/XMLSchema#string

P407

P433

41

http://www.w3.org/2001/XMLSchema#string

P478

102

http://www.w3.org/2001/XMLSchema#string

P50

P577

2005-09-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7564757

http://www.w3.org/2001/XMLSchema#string

P698

16199516

http://www.w3.org/2001/XMLSchema#string

P921

antiretroviral drug

P932

1253583

http://www.w3.org/2001/XMLSchema#string